Table 3 Linear regression analysis: Association between adiponectin and clinical characteristics
Dependent variable | Estimate (95% CI) | P |
|---|---|---|
Total adiponectin | Â | Â |
   Intercept | 9.4 (-0.5, 19.3) |  |
   Latino | -4.5 (-6.4, -2.5) | <0.0001 |
   Age (per 5 years) | 0.7 (0.2, 1.2) | 0.0041 |
   Female Gender | 3.7 (1.8, 5.6) | 0.0027 |
   TZD use | 5.1 (2.2, 8.0) | 0.0001 |
   BMI (per 5 kg/m2) | -1.0 (-1.5,-0.2) | 0.0054 |
   Statin use | -2.4 (-4.3,-0.6) | 0.0104 |
   Estimated GFR (per ml/min) | -0.02 (-0.05, 0.02) | 0.41 |
   Diabetes | -0.3 (-2.3, 1.7) | 0.76 |
HMW adiponectin | Â | Â |
   Intercept | 4.4 (-1.0, 9.9) |  |
   Latino | -1.6 (-2.7, -0.5) | 0.0047 |
   Age (per 5 years) | 0.3 (0.1, 0.6) | 0.0122 |
   Female Gender | 1.4 (0.3, 2.4) | 0.0107 |
   TZD use | 2.9 (1.3, 4.5) | 0.0007 |
   BMI (per 5 kg/m2) | -0.5 (-1.0,-0.15) | 0.0083 |
   Statin use | -0.9 (-1.9, 0.2) | 0.1007 |
   Estimated GFR (per ml/min) | -0.008 (-0.03, 0.01) | 0.4176 |
   Diabetes | -0.5 (-1.6, 0.6) | 0.4029 |